Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells

Cancer Research

Volumn 61, Issue 18, 2001, Pages 6768-6776

  Syed, Viqar ^a   Ulinski, Gregory ^a   Mok, Samuel C ^b   Yiu, Gary K ^b   Ho, Shuk Meia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CLOMIFENE; GONADOTROPIN RECEPTOR; HORMONE RECEPTOR; SEX HORMONE;

ARTICLE; CANCER RISK; CELL IMMORTALIZATION; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GROWTH REGULATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; OVARY TUMOR; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; CELL DIVISION; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ESTRADIOL; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HORMONES; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PROGESTERONE; RECEPTORS, FSH; RECEPTORS, LH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 0035884589     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Ovarian cancer: Epidemiology, biology, and prognostic factors
2. Pathology of ovarian cancer precursors
3. Endocrine factors in common epithelial ovarian cancer
4. Factors affecting the association of oral contraceptives and ovarian cancer
5. Determinants of ovarian cancer risk. I. Reproductive experiences and family history
6. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer
7. Review: Gonadotropins and development of ovarian cancer
8. Ovulation induction for infertility: Is it safe or not?
9. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
10. Etiology of ovarian cancer: A proposed mechanism
11. Menopause and ovarian cancer
12. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study
13. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer
14. An epidemiologic study of epithelial carcinoma of the ovary
15. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women
16. Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence
17. The adverse effects of hormone replacement therapy
18. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women
19. Parity, age at first childbirth, and risk of ovarian cancer
20. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines
21. Androgen receptors and effects of sex hormones on growth of a human ovarian carcinoma cell line
22. Hormonal carcinogenesis
23. Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones
24. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth
25. Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro
26. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone
27. Gonadotropins stimulate the proliferation of human epithelial ovarian cancer cell
28. Ovarian cancer and gonadotropins in vitro: New evidence in favor of independence
29. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro
30. The growth response of BG-1 ovarian carcinoma cells to estradiol, 4OH-tamoxifen, and tamoxifen: Evidence for intrinsic antiestrogen activation
31. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1
32. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors
33. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model
34. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells
35. BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro
36. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen
37. Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands
38. Aging and development of ovarian epithelial carcinoma: The relevance of changes in ovarian stromal androgen production
39. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs)
40. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines
41. Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene
42. Expression and function of estrogen receptor subtypes in granulosa cells: Regulation by estradiol and forskolin
43. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameter
44. Progesterone is an autocrine/paracrine regulator of human granulosa cell survival in vitro
45. Cloning and sequenceing of human FSH receptor cDNA
46. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate
47. Gonadotropic hormone binding to human ovarian tumors
48. Localization of gonadotropin binding sites in human ovarian neoplasms
49. LH(hCG) receptor in benign and malignant tumors of human ovary
50. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers
51. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer
52. The ovaries and the breasts
53. Gonadotropins at menopause: The influence of obesity, insulin resistance, and estrogens
54. Serum gonadotropins and steroid hormones and the development of ovarian cancer
55. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer
56. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies
57. Hormone replacement therapy and risk of epithelial ovarian cancer
58. Estrogen replacement therapy and ovarian cancer risk
59. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women
60. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
61. Estrogen replacement therapy and risk of epithelial ovarian cancer
62. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age
63. 3H]estrone to the estrogen receptor
64. Menopausal experiences and bone density of Mayan women in Yucatan, Mexico
65. 5α-Reductase and 17β-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate
66. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells
67. Menopause related changes of adrenocortical steroid production
68. Endocrinology of pregnancy